Results 41 to 50 of about 5,881 (166)
XPO1-dependency of DEK::NUP214 leukemia
Abstract The nuclear export protein XPO1 interacts with nucleoporin 214 (NUP214) and has been implicated in the pathogenesis of SET::NUP214 acute myeloid leukemia (AML). We evaluated DEK::NUP214 (DN), characterizing a distinct AML entity, for its dependency on XPO1 in human AML models.
Fiorella Charles Cano +13 more
openaire +2 more sources
XPO1 Inhibitor Approved for Multiple Myeloma [PDF]
Abstract The FDA granted accelerated approval to selinexor plus low-dose dexamethasone for triple-class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data.
openaire +1 more source
MiR‐483‐3p improves learning and memory abilities via XPO1 in Alzheimer's disease
Introduction Alzheimer's disease (AD), a common form of dementia, has been reported to influence 27 million individuals globally. Several risk factors including oxidative stress, gut microbiota imbalance, and cognitive activity are reported to be closely
Gang Luo, Xiaoyan Wang, Changya Liu
doaj +1 more source
Cytology‐First Diagnostic Workflow for Melanoma of Unknown Primary With Molecular Profiling
Cytology‑first diagnostic workflow for melanoma of unknown primary. Fine‑needle aspiration of an enlarged lymph node enables rapid cytologic evaluation and immunocytochemical confirmation of melanocytic lineage (SOX10). This early cytologic diagnosis facilitates timely surgical excision and comprehensive genomic profiling, supporting integrated ...
Hong Yu +3 more
wiley +1 more source
XPO1 (exportin 1 (CRM1 homolog, yeast)) [PDF]
Review on XPO1 (exportin 1 (CRM1 homolog, yeast)), with data on DNA, on the protein encoded, and where the gene is implicated.
Ruggiero A, Giubettini M, Lavia P
openaire +4 more sources
To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino +16 more
wiley +1 more source
Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture +3 more
wiley +1 more source
Objectives Aberrant nucleocytoplasmic transport mediated by Exportin 1 (XPO1) contributes to leukemogenesis, yet the molecular basis underlying the limited efficacy of the XPO1 inhibitor Selinexor in acute myeloid leukemia (AML) remains unclear.
Chunli Xu +5 more
doaj +1 more source
USP34 Haploinsufficiency as a Cause of Neurodevelopmental Phenotypes
Heterozygous loss‐of‐function variants in USP34 cause a novel neurodevelopmental disorder characterized by global developmental delay, speech impairment, autism, hypotonia, craniofacial dysmorphism, and distal limb anomalies. Disrupted Wnt/β‐catenin signaling via reduced Axin stabilization refines gene‐specific contributions within 2p15p16.1 ...
Helena Wigoda +10 more
wiley +1 more source
Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer [PDF]
Objetivos: La exportina 1(XPO1), una proteína exportadora nuclear, ha ido ganando reconocimiento en la progresión y el tratamiento del cáncer. Este estudio tuvo como objetivo evaluar la asociación entre la sobreexpresión de XPO1 con NF-κB, Ki67 y las características clinicopatológicas en muestras de tejido de cáncer colorrectal (CCR) y explorar el ...
Mohammed Ali Al-Adhraei +3 more
openaire +2 more sources

